Listen to our scientists and collaborators discuss the latest progress in M4K Pharma’s quest for a medicine for DIPG- a deadly children’s brain cancer.

In this meeting, the team provides a comprehensive summary of the project accomplishments at the one year mark. We also highlight the discovery and profile of M4K2009, a selective, orally bioavailable and brain penetrant ALK2 inhibitor. M4K plans to make this molecule available to the broader scientific community by the end of February, 2019.

Everyone is invited to dial-in and join our live meetings. To find out when our next meeting will be, follow us on twitter: @M4KPharma